Natalie Kirchhofer 博士

Germany becomes ready for the UPC and revises Patent Act

Germany revises Patent Act and clears way for UPC

COHAUSZ & FLORACK successful in defending Bayer’s patent on the once-daily administration of rivaroxaban (Xarelto®)

Patenting plant inventions via the EPO after G 3/19

EUIPO sees significant rise in EU trademark applications in 2021

Double patenting – Art. 125 EPC provides legal basis for refusing a European patent application

Second medical use patents and their potential for society and research

EPO Enlarged Board of Appeal postpones decision on video-hearings

EPO video-hearings: Enlarged Board of Appeal reviews challenges on grounds of suspected partiality and exchanges board members

Dr. Regina Hock is the new President of the Federal Patent Court

Comment on oral hearings at the EPO: Leading patent attorney firms consider compulsory video conferences unlawful

EPO's Enlarged Board of Appeal to review new compulsory videoconferencing practice

EPO Boards of Appeal to apply video conferencing rule as early as January 1, 2021

Second medical use claims in pharmaceutical patents – sharp sword or toothless tiger?

Oral proceedings via video conference: The EPO Boards of Appeal propose to amend the Rules of Procedure

EPO decision on compulsory oral proceedings by videoconference

Jennifer Doudna and Emmanuelle Charpentier win the 2020 Nobel Prize in Chemistry for CRISPR/Cas

Specialisation in life sciences, pharma and chemical disputes

New draft legislation in Germany to ratify the Unified Patent Court

Deadly pitfalls and lessons learned – claiming priority at the EPO

European Patent Office denies patentability of plants and animals obtained by essentially biological processes (G 3/19 "Pepper")

Patent battle over CRISPR – EPO revokes foundational patent of the Broad Institute in last instance for formal priority defects

Handbuch Europäischer Patentprozess

New Rules of Procedure of EPO Boards of Appeal Entering into Force on January 1, 2020

EPO Administrative Council adopts new Rules of Procedure for the Boards of Appeal

Clinical trial disclosures – an obstacle to patentability in Europe

Structural reform at the EPO shows first positive results

Sprycel – new plausibility threshold for life sciences patents?

The need-to-know facts about patent term extensions in Europe

Constructive Discussion Between EPO President, Patent Attorneys, and Attorneys at Law

Patent pools in the life sciences: a potential facilitator of CRISPR commercialisation

UPC could open as early as December 2017, if not blocked by a “hard” Brexit

Using the UPC to your benefit in pharmaceuticals and life sciences

Proposed structure of the Unified Patent Court

Cross-border patent litigation in Europe: change is coming

Das Patentassessorexamen, Skript zur Prüfungsvorbereitung

Prodrugs and metabolites - in the twilight zone of patentability?

The must-know facts about patent term extensions in Europe

EPO Enlarged Board of Appeal rules on disclaiming positive embodiments of an invention

Key issues in building a strong life sciences patent portfolio

Patenting biotechnology inventions via the EPO

Patent-Life Cycle-Management im Pharmabereich